Abstract
The Glaucoma Laser Trial (GLT) was an investigator-initiated, grant-supported, multicenter, randomized, controlled clinical trial designed to investigate the efficacy and safety of argon laser trabeculoplasty (ALT) as an alternative to medical treatment for newly diagnosed primary open-angle glaucoma (POAG). One eye of each patient was randomly assigned to ALT followed by medical treatment if needed to control intraocular pressure (IOP). The patient's other eye was assigned to medical treatment. Medical treatment for either eye was prescribed according to a stepped sequence. Patients were followed for a minimum of 2 years. Monitoring for control of IOP and for adherence to the protocol continued throughout the followup period. This article describes the design and methods of the trial and provides a discussion of the underlying rationale for key design decisions.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
